SCHEMBL5559527

SCHEMBL5559527

CC(C)Cc1ccccc1-c1ccc(C(=O)O)c(Cc2cccc3ccccc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.54
SGK1 O00141 1/20 0.48
CAMKK2 Q96RR4 1/20 0.48
MCL1 Q07820 5/20 0.47
ACMSD Q8TDX5 1/20 0.46
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE1C Q14123 1/20 0.44
PTGER4 P35408 1/20 0.44
DHODH Q02127 1/20 0.43
ADRB3 P13945 2/20 0.41
ADRB1 P08588 1/20 0.41
FDPS P14324 1/20 0.41
P2RX3 P56373 1/20 0.41
BAD Q92934 2/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5554733 0.85 BCL2L1 (0.55) BCL2L1MCL1ACMSDPDE1APDE1B
SCHEMBL5554382 0.83 BCL2L1 (0.50) BCL2L1MCL1ACMSDPDE1APDE1B
SCHEMBL5559504 0.82 BCL2L1 (0.74) BCL2L1MCL1PDE1APDE1BPDE1C
SCHEMBL5559016 0.79 BCL2L1 (0.53) BCL2L1MCL1PDE1APDE1BPDE1C
SCHEMBL5559498 0.78 BCL2L1 (0.46) BCL2L1MCL1PDE1APDE1BPDE1C
SCHEMBL19420098 0.73 BCL2L1 (0.75) BCL2L1MCL1PDE1APDE1BPDE1C
Hydrochloric Acid SCHEMBL5704000 0.72 DCLRE1B (0.62) SGK1CAMKK2MCL1ACMSDADRB3
SCHEMBL14347691 0.72 BCL2L1 (0.71) BCL2L1MCL1PDE1APDE1BPDE1C
SCHEMBL17805815 0.72 BCL2L1 (0.84) BCL2L1MCL1PDE1APDE1BPDE1C
SCHEMBL19425571 0.71 BCL2L1 (0.83) BCL2L1MCL1PDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1594512-A4 COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION KEMIA INC (US) 2007-07-11 EP disclosed
EP-1594512-A2 COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION Kemia, INC. (US) 2005-11-16 EP disclosed
US-20040248850-A1 Compounds for the treatment of HIV infection KEMIA, INC. 2004-12-09 US disclosed
WO-2004071426-A2 COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION KEMIA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248850-A1 Compounds for the treatment of HIV infection CCR5, CD4, HAVCR2 BCL2L1 2807/4885SGK1 2516/4885CAMKK2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.